MedTrace Logo

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

NCT00377780 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-09-23

No results posted yet for this study

Summary

This is an open phase II study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®), trastuzumab (Herceptin®), and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu positive breast cancer.

Conditions

Interventions

DRUG

Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

max. 6 courses

Sponsors & Collaborators

  • Cephalon

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Laurence J.C. van Warmerdam

    lead OTHER

Principal Investigators

  • Laurence J. van Warmerdam, MD, PhD · Catharina Ziekenhuis Eindhoven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00377780 on ClinicalTrials.gov